Led · Series A · Mar 2026

R1 Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for patients with kidney disease. Its lead program, AP306, targets hyperphosphatemia in patients with chronic kidney disease on dialysis and is described as a pan phosphate active transport inhibitor that blocks three key phosphate transporters in the gut. R1 positions AP306 as designed to deliver rapid and effective phosphate lowering with a reduced treatment burden. The company is partnering with Alebund on AP306 and plans to start a Phase 2b study later this year. R1 is led by Co-Founder, President and CEO Krishna Polu and is based in Redwood City, CA. The company strengthened its balance sheet with a $77.5M Series A to support its global development program.

Participated · Series B · Mar 2026

Greater Good Health partners with health plans, hospital systems, and provider groups to offer nurse practitioner–led primary care clinics and embedded clinical programs that lower total cost of care while improving quality and access. The company currently serves more than 200,000 patients through its clinics and integrated services platform, achieving 4-plus STAR quality scores, over 200 % growth in preventive-care engagement, reduced unnecessary acute admissions, and a Net Promoter Score above 90. Its first three clinics launched in Montana with Humana, and a fourth clinic opened in Idaho with Blue Cross of Idaho, highlighting the model’s scalability in underserved, aging markets. Based in El Segundo, California, Greater Good Health focuses on Medicare adults and addresses the national shortage of primary care physicians by elevating nurse practitioners to lead care teams. The organization functions as an extension of risk-bearing entities, supplying the infrastructure and staffing needed for longitudinal, value-based care management. With fresh capital, the company plans to deepen payer partnerships, strengthen its technology-enabled care platform, and expand into additional geographies.

Participated · Series B · Aug 2024

Pathalys Pharma is a late-stage clinical biopharmaceutical company based in Research Triangle Park, NC, focused on therapies for end-stage kidney disease (ESKD). Its initial asset is upacicalcet, a novel calcimimetic intended to improve treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. The company is running two ongoing clinical trials of upacicalcet and intends to use new financing to finalize those studies. Pathalys plans to execute an NDA filing with the U.S. Food and Drug Administration and accelerate preapproval commercialization preparations. Beyond upacicalcet, the company continues to identify additional needs and potential therapeutic solutions for patients with ESKD. The recent financing is intended to support late-stage development, regulatory submission, and commercialization readiness. Pathalys Pharma is a private, late-stage clinical biopharmaceutical company focused on developing advanced therapeutics for end-stage kidney disease (ESKD). Its lead asset is upacicalcet, a novel calcimimetic aimed at improving treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. The company is led by CEO Neal Fowler and continues to identify other high-priority needs and potential solutions for patients with ESKD. Pathalys has entered a collaboration with Launch Therapeutics to advance the phase 3 clinical trials for upacicalcet; Launch Therapeutics is backed by funds managed by Carlyle and Abingworth. The recently announced financing will support two phase 3 trials, regulatory registration efforts, and pre-commercialization activities for upacicalcet. Pathalys remains a privately held, late-stage clinical-stage biopharma working toward commercialization of its initial asset.

Participated · Series D · Aug 2023

Xeltis develops implantable vascular and cardiovascular devices based on its Restorex® platform, which uses an advanced polymer implant that transforms into the patient’s own tissue and is gradually absorbed. Its lead product, aXess™, is an implantable blood vessel for hemodialysis vascular access that has received CE Mark approval and is being commercially deployed in Europe. The company is enrolling a US pivotal trial of aXess™ (now >50% enrolled) and is preparing for FDA submission and a US market launch. Xeltis plans to use recent funding to support European commercial rollout, upscale manufacturing and advance its XABG and XPAD clinical programs. Financially, the company raised €50m in 2025 from the European Investment Bank and existing shareholders and added €20.5m in 2026 from new and existing investors to fund its next phase of clinical, regulatory and commercial execution.

Participated · Equity · May 2023

Dock Health offers a web and mobile administrative hub that centralizes HIPAA-compliant task management and administrative workflow automation for clinical and administrative teams. The platform was developed at Boston Children’s Hospital and spun out in 2020; thousands of healthcare teams use Dock daily. Core features include integrations and APIs to sync EHR and productivity systems, SmartFlow digital workflows with automations and branching logic, and plans for AI-supported workflows. Dock intends to build an integrations marketplace, an analytics and insights dashboard to surface workflow bottlenecks, and an administrative best-practices community. The company accelerated adoption during the pandemic through robust APIs and professional services. Recent funding will support product and technical development and growth of the employee base.